CapeStart Helps Life Science Teams Scale Faster, Boost Productivity with New Release of MadeAi™, Award-Winning GenAI Platform
Article content
MadeAi-LR solution now supports AI-aided Review, AI as Reviewer, Summary- and Arm-Level Extraction, and Built-in Quality Appraisal—cuts literature review time in half and delivers 90% accuracy
Article content
Article content
MONTREAL & CAMBRIDGE, Mass. — At today's ISPOR Montreal 2025 Conference, CapeStart, Inc. announced a major new release of MadeAi™—its award-winning generative AI-based platform that expedites the synthesis of content and data for the life sciences, helping time-strapped teams to scale faster, strengthen regulatory submissions, and advance the pace of scientific research.
Article content
MadeAi first launched in November of 2024 with MadeAi-LR, a GenAI-enabled software solution leveraging the MadeAi platform to streamline key applications used in new therapy development including systematic literature reviews (SLR), clinical evidence reports (CERs), meta-analysis, targeted literature reviews (TLRs), and other clinical literature assessments. MadeAi-LR cuts literature review time in half while centralizing the process with an end-to-end platform, delivering 90% accuracy, and providing sourcing and attribution along the way for verifiable, traceable, and trustworthy results.
Article content
MadeAi's new release introduces advanced features for more complex literature review execution and content synthesis, including:
Article content
Support for AI-aided Review and AI as Reviewer capabilities for both Title & Abstract Screening and Full-text Screening. For the AI-aided Review mode, AI-generated suggestions are shared with two blinded human reviewers to facilitate faster, more informed decisions. For the AI as Reviewer mode, one human reviewer works in parallel with the AI, which serves as the second reviewer—reducing manual workload without compromising review quality.
Expanded and customizable Screening model, offering more than a dozen screening criteria including PICOS. In addition, user-defined criteria are also supported to accommodate projects with novel screening needs.
More dynamic Extraction, providing a Summary-level Extraction and an Arm-level Extraction. Summary-level Extraction is ideal for internal desk research, offering a consolidated view of key information from each study. For more detailed insights, Arm-level Extraction provides a granular breakdown of outcomes across different study groups, showing the user the origin of the extracted content, making reviewing and editing fast and efficient.
AI Agent-Enhanced Extraction, enabling the ability to extract information from text, tables, graphs, and figures.
Quality Appraisal built into the MadeAi workflow, allowing users to assess the risk-of-bias for included articles and visualize the results through intuitive tables and charts.
Article content
Developed with top 15 pharmaceutical companies, MadeAi-LR centralizes the literature review workflow, while bringing full sourcing attribution and transparency into research decision considerations. It frees teams to focus on higher-value work while driving greater productivity, stronger regulatory submissions, sharper internal strategies, and deeper research. With a single review demanding hundreds of onerous hours, MadeAi-LR helps pharma, biotech, and medtech organizations save time, stretch critical resources, and scale research to accelerate innovation.
Article content
'MadeAi-LR customers are completing more literature reviews in less time and seeing immediate ROI, and they're eager for us to evolve our platform to address their more complex research needs,' said Gaugarin Oliver, founder and CEO of CapeStart. 'Our latest release offers enhancements that allow the GenAI to support more dynamic aspects of literature review research—including AI as Reviewer, Arm-level Extraction, and Quality Appraisals, among other improvements—so teams can scale faster and focus on what matters most: advancing science.'
Article content
Since MadeAi's launch in 2024, the platform has been recognized for AI excellence in life sciences several times over. It received a Stevie® award in the 21st Annual International Business Awards® program, where it was recognized as an innovative Artificial Intelligence/Machine Learning Solution in Healthcare within the Business Technology category. The platform was also named a PM360 2024 Innovator in the Generative AI Category. And most recently, MadeAi was named a winner of the 2025 Artificial Intelligence Excellence Awards, presented by the Business Intelligence Group.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contacts:
Meghan Oates-Zalesky
Chief Marketing Officer for CapeStart
Meghan.Oates@capestart.com
617-435-2470
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Seasonique birth control pills from Teva Canada recalled due to extra yellow tablets
Social Sharing Health Canada issued a recall notice on Friday for some Seasonique birth control products due to some packages containing the correct blue-green pills coming with extraneous yellow tablets. The agency says the recall is for the 0.01-milligram ethinyl estradiol, 0.03-milligram ethiny lestradiol and 0.15-milligram levonorgestrel Seasonique pills made by Teva Canada. Health Canada said those who find the yellow pills should not consume them and return the product to a pharmacy for a replacement or alternative, adding that those who can't return them right away should continue taking the regular blue-green tablets as instructed until they are able to return them. "If you took a yellow pill instead of a blue-green pill ... or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional," the agency said. Friday's contraceptive pill recall is the latest by Teva Canada. On Thursday, it recalled its Seasonale pills (0.15-milligram levonorgestrel and 0.03-milligram ethinyl estradiol) due to white placebo pills being found among the regular pink tablets. And in May, Teva Canada had to recall the same Seasonique tablets recalled on Friday due complaints that packages were missing some pills.
CBC
an hour ago
- CBC
Health authority interim CEO calls for further integration of AI into health care
Social Sharing Nova Scotia needs to merge artificial intelligence into the health-care system by way of a research centre, says the interim CEO of the Nova Scotia Health Authority. At a panel discussion on Friday at the Halifax Chamber of Commerce, Karen Oldfield said AI has been introduced to the health-care system in small amounts, but more needs to be done. "We have to lay this foundation," Oldfield said. "But to get to the predictive analytics, to wellness, to precision medicine, we have to have this." Oldfield says that the next logical step for the province is to develop a centre of excellence, meaning a hub dedicated to overseeing and researching AI. Oldfield expanded on this, saying AI would improve clinical efficiency and administration. Oldfield said AI could be used to determine a population or community with a higher likelihood of contracting diseases, like certain kinds of cancer. "If we can predict, then we can get ahead of it," said Oldfield. "That's really where most provinces and most countries want to get.... That's where we need to head." Oldfield says the development of such a centre would be dependent on people more than money. "We need the researchers that are able to use that data …to develop their algorithms that can lead us to predictive analytics and precision medicine," said Oldfield. The proposed AI centre for excellence is only in its early stages. Oldfield says she has had conversations about a centre with the Atlantic Canada Opportunities Agency and various members of the federal government.
CTV News
an hour ago
- CTV News
Local unemployment rate up to 6.9 per cent in May
London's unemployment rate is rising as people struggle to find work in the current labour market. According to Statistics Canada, the jobless rate in the region rose half a percentage point to 6.9 per cent in May. Approximately 1,700 jobs were lost locally, amid trade tensions with the United States. Nationally, unemployment has increased for three consecutive months, reaching seven per cent in May. This is the highest unemployment rates have been in nearly a decade, with 1.6 million people unemployed.
